Tempus AI stock surged 24%, benefiting from Moderna and Merck's cancer vaccine progress and its acquisition of Personalis.
Tempus AI shares surged 24% after Moderna and Merck announced positive late-stage melanoma results, The Wall Street Journal reported. Tempus AI acquired Personalis for $16.25 per share (totaling $1.5 billion) on July 20. Personalis has been involved in Moderna's clinical programs and is expected to benefit from the "gold rush" in personalized cancer therapies.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Anthropic launches AI agent Claude Duet, capable of continuous background operation and proactive task execution
-
2
Three companies have notified the U.S. SEC of their plans to launch tokenized stock trading.
-
3
Treasury Secretary Bessent dismisses 'systemic' AI risks
-
4
Blackstone Executives Say Concerns About AI Infrastructure Debt Are Overblown
-
5
OpenAI says its AI model found a critical PHP vulnerability, leading to government websites in multiple countries going offline.
-
6
Robert Sicari, a former Brevan Howard fund manager, has been sued by a quant trader colleague at his new fund, who alleges Sicari withheld millions of dollars in trading profits.
-
7
CICC: Suggest increasing gold allocation to hedge AI asset risks, dollar depreciation trade is an effective strategy
-
8
Treasuries Slide After Middle East Strife Report Spurs Oil Gains
-
9
OpenAI to bring its AI models to Google Cloud, expanding beyond Microsoft to all three top cloud providers
-
10
Australian superannuation fund UniSuper is avoiding direct investments in data centers, believing the biggest winners from the AI boom will be technology application companies rather than infrastructure builders.
Markets Today
Recommended Reading


